Table 2.
The results of SARS-CoV-2 neutralization antibodies in 127 cases classified by demographic characteristics.
| Item | Positive Group | Negative Group | t/x2 | p Value |
|---|---|---|---|---|
| N = 127 | 66 | 61 | ||
| Sex Male | 17 (47.22%) | 19 (52.78%) | 0.453 | 0.501 |
| Female | 49 (53.85%) | 42 (46.15%) | ||
| Age (years) | 35.06 ± 10.28 | 38.05 ± 10.83 | −1.595 | 0.113 |
| 20–29 | 24 (60.00%) | 16 (40.00%) | 1.724 | 0.632 |
| 30–39 | 21 (50.00%) | 21 (50.00%) | ||
| 40–49 | 15 (48.39%) | 16 (51.61%) | ||
| ≥50 | 6 (42.86%) | 8 (57.14%) | ||
| Height (cm) | 166.05 ± 7.43 | 165.11 ± 6.98 | 0.732 | 0.465 |
| Weight (kg) | 63.26 ± 11.78 | 62.48 ± 10.16 | 0.393 | 0.695 |
| BMI (kg/m2) | 22.83 ± 3.09 | 22.88 ± 3.25 | −0.090 | 0.929 |
| ≥24 | 24 (54.55%) | 20 (45.45%) | 0.179 | 0.672 |
| <24 | 42 (50.60%) | 41 (49.40%) |
127 participants who had completed COVID-19 vaccination (inactivated SARS-CoV-2 vaccine, 64; CoronaVac, 61; CanSino, 2). BMI: body mass index.